In recent years, growing concerns over the reproducibility of routine assessment of breast cancer biomarkers by IHC with reported discordance rates of up to 20 % for ER and HER2, have motivated the development of detailed guidelines to improve the accuracy of testing [10–13]. This evidence concerns the gene ESR1 and breast carcinoma.